[O3] Oral Session 3　Hematologic Malignancies
【E】

[O3-5] Long-Term Analysis of ZUMA-5 Phase 2 Study of Axicabtagene Ciloleucel in Patients With Indolent Non-Hodgkin Lymphoma

^○Sattva S. Neelapu¹, Julio C. Chavez², Alison R. Sehgal³, Narendranath Epperla⁴, Matthew Ulrickson⁵, Emmanuel Bachy⁶, Pashna N. Munshi⁷, Carla Casulo⁸, David G. Maloney⁹, Sven De Vos¹⁰, Ran Reshef¹¹, Lori A. Leslie¹², Olalekan O. Oluwole¹³, Ibrahim Yakoub-Agha¹⁴, Rashmi Khanal¹⁵, Joseph Rosenblatt¹⁶, Marika Sherman¹⁷, Jinghu Dong¹⁷, Alessandro Giovanetti¹⁷, Yin Yang¹⁷, Christine Lui¹⁷, Zahid Bashir¹⁷, A. Scott Jung¹⁷, Caron A. Jacobson¹⁸ (1.The University of Texas MD Anderson Cancer Center, 2.University of South Florida H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA, 3.UPMC Hillman Cancer Center, Pittsburgh, PA, USA, 4.The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA, 5.Banner MD Anderson Cancer Center, Gilbert, AZ, USA, 6.Centre Hospitalier Lyon Sud, Pierre-Bénite, France, 7.Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA, 8.University of Rochester Medical Center - James P. Wilmot Cancer Center, Rochester, NY, USA, 9.Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 10.Ronald Reagan University of California Los Angeles Medical Center, Santa Monica, CA, USA, 11.Columbia University Herbert Irving Comprehensive Cancer Center, New York City, NY, USA, 12.John Theurer Cancer Center, Hackensack, NJ, USA, 13.Vanderbilt University Medical Center, Nashville, TN, USA, 14.CHU de Lille, Univ Lille, INSERM U1286, Infinite, 59000 Lille, France, 15.Fox Chase Cancer Center, Philadelphia, PA, USA, 16.University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA, 17.Kite, a Gilead Company, Santa Monica, CA, USA, 18.Dana-Farber Cancer Institute, Boston, MA, USA)